Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels

Colorectal cancer (CRC) resistance to fluoropyrimidines and other inhibitors of thymidylate synthase (TS) is a serious clinical problem often associated with increased intracellular levels of TS. Since the tumour suppressor gene p53, which is mutated in 50% of CRC, regulates the expression of severa...

Full description

Saved in:

Bibliographic Details
Main Authors:	Giovannetti, E, Backus, H H J, Wouters, D, Ferreira, C G, van Houten, V M M, Brakenhoff, R H, Poupon, M-F, Azzarello, A, Pinedo, H M, Peters, G J
Format:	Artigo
Language:	Inglês
Published:	Nature Publishing Group 2007
Subjects:	Translational Therapeutics
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC2360080/ https://ncbi.nlm.nih.gov/pubmed/17339891 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603639
Tags:	Add Tag No Tags, Be the first to tag this record!

Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels

Similar Items